Biopure公司

2022年9月6日

根據最近的一項估計Emergen研究,合成血液替代品的市場全球預計到2027年將達到154億美元。由於他們擴大使用條件如心血管疾病、貧血、惡性腫瘤、損傷、新生兒情況下,產婦條件,器官移植,和其他條件,合成血液替代品如Hemopure, Oxyglobin, Hemotech正在經曆兩位數的市場增長。此外,需要人工血液替代品可能受產科與輸血相關的問題,如果管理不當,可能導致並發症,甚至死亡。極度不適的患者,利用人工血液或血液紅細胞的替代品。唯一的人造血液的功能是提供氧氣和二氧化碳。組件沒有完全有能力執行的血紅細胞的功能。在即將到來的一年,市場預期的上漲需要輸血。此外,努力生產有效的人體人工氧載體正在增長。例如,美國化學學會研究人員試圖創建合成血紅細胞在2020年6月,複製自然的功能。這些是主要的趨勢,現在的行業。 One of the major factors impacting the growth of the industry is the lack of human blood for transfusions. A surgical procedure or traumatic injury results in the need for transfusions for more than 4.5 million Americans each year, and the demand for transfusions is outpacing the supply. The Pacific Heart, Lung, and Blood Institute reports that there is a severe shortage of human blood that can be used for medical procedures. In their lifetime, around 33.0% of Americans are predicted to require a transfusion due to a serious life-threatening condition. Since current projections do not account for the need for blood in situations of major civilian fatalities, terrorist attacks, and conflicts, which would drive market demand, the shortage in the coming years could be severe. Some Key Highlights from the Report : In September 2019, KaloCyte, a preclinical-stage biotech company working on creating a synthetic RBC replacement for use in situations where stored RBCs are not available, formed an association with Baltimore’s expanding biotech scene as a member of the University of Maryland (UM) BioPark. The hemoglobin obtained from a particular strain of E. coli bacterium is used to make synthetic hemoglobin-based replacements. In comparison to RBCs, the modified hemoglobin is more stable and has a better oxygen-carrying capacity. Low hemoglobin levels, percutaneous coronary intervention, coronary artery bypass grafting, non-ST-segment elevation acute coronary syndromes, and other conditions frequently require the administration of blood transfusions to patients. Thus, cardiovascular illnesses constitute a prominent application area for the market. The market for artificial blood substitutes is growing as a result of increasing strategic efforts by key market players to raise consumer awareness of these products. The artificial blood replacements market also offers you a thorough study of each country’s market growth. Additionally, it gives specific information about the positioning of market participants geographically. The historical timeframe for the data is from 2010 to 2019. Key participants include Hemarina, Sagart Corporation, FLUORO2 Therapeutics, Biopure Corporation, Alpha Therapeutic Corporation, KaloCyte, Baxter, Green Cross Corporation, North Field Laboratories, and Alliance Pharmaceutical Corporation, among others. Emergen Research has segmented the global synthetic blood substitutes market based on source, type, application, end-user, and region: Source Outlook (Revenue, USD Billion; 2017-2027) Human Blood Hemoglobin-Based Oxygen Carriers (HBOCs) Cardiovascular Diseases Hospitals & Clinics North America